Bavarian Nordic Strengthens its Commercial Organisation and Updates on Pipeline Progress

Bavarian Nordic A/S will establish a new separate sales- and marketing function in order to strengthen the company's commercial activities and increase the sales promotion for its third generation smallpox vaccine, IMVAMUNE and future vaccines, including HIV and cancer vaccines.

The commercial function will, besides intensifying the sales promotion of IMVAMUNE, ensure that the company's research and development is going in a commercial way to a still higher extent, and that necessary market knowledge at an early stage is integrated in the decision-making processes within clinical development.

For further information please contact:

Anders Hedegaard,

President & CEO

Tel: +45 33 26 83 83

Email: bn@bavarian-nordic.com

Or visit: www.bavarian-nordic.com

Home > News & Events > News > Bavarian Nordic Strengthens its Commercial Organisation and Updates on Pipeline Progress
Last updated: 2007-09-21

The official Medicon Valley site is brought to you by the organisations Region Skåne and Copenhagen Capacity - in association with Medicon Valley Alliance

Contact:
Copenhagen Capacity,	tel: +45 33 22 02 22
Region Skåne,	tel: +46 (0)40 623 97 48

BAVARIAN NORDIC A/S

BAVARIAN NORDIC A/S

Founded 1994, Bavarian Nordic is a leading international biopharmaceutical company developing, producing and marketing innovative vaccines to prevent and treat infectious diseases and cancer. With operations in Denmark, Germany, the USA, and Singapore, Bavarian Nordic employs over 200 people and is ...